ReviewFrontiers in bioengineering and biotechnology2026
Clinical biomarkers and biosensors for early detection of metabolic dysfunction-associated steatohepatitis (MASH): a translational perspective.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) is a long-term chronic liver disease condition that stems from nonalcoholic fatty liver disease (NAFLD) and results from multiple factors, including lifestyle, metabolic dysfunction, and genetic predisposition. The increasing prevalence of NAFLD in the global population is expected to reach over 35% by 2030. It thus has become a significant public health concern because of its association with metabolic syndrome, cardiovascular diseases, diabetes mellitus, and hepatocellular carcinoma. Therefore, early diagnosis is crucial to avoid further liver disease complications and to provide early and effective patient care. Though there are diagnostic measures available for NASH/MASH detection, like biopsy and serological assays, these are mostly invasive and do not provide the complete picture of the liver condition. Point-of-care diagnostics like biosensors can help overcome these limitations by allowing for a rapid, inexpensive, and more straightforward diagnostic method that also aligns with the present global health needs. Moreover, integrating artificial intelligence and machine learning approaches for automated analysis alongside real-time cloud-based reporting and telehealth interfaces can potentially aid in expanding the utility of these systems into integrated diagnostic systems. Through this review, we aim to address the interplay of technological innovation, public health significance, and implementation barriers in advancing biosensor diagnostics for effective and reliable detection of NASH/MASH for better liver health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.